Company Overview

Company name: MPX Bioceutical (CNQ: MPX)
Description: Producer of medical marijuana and pharma-grade products in North America. The company runs a vertically integrated operation to cultivate high-quality cannabis flower, oil and extracts which are available online and in storefronts, enabling patients with consistent high quality, efficacious cannabis and other natural products.
Year founded: 1974
Parent company:
Industry: Healthcare | Group: Pharmaceuticals and Biotechnology | Code:
Website: www.mpxbioceutical.com
Employees:
City: Toronto
State: Ontario
Country: Canada
Region: Americas

Financial Highlights

Start up capital raised (USD Million): 70.96
Business status: Profitable
Ownership: Publicly Held
Exchange: CNQ
Ticker: MPX
Revenue (USD Million): 29.37
Gross profit (USD Million): 11.26
Net income (USD Million) -22.94
Enterprise value: 253.94
Earnings before interest, tax, depreciation and amortization (EBITDA): -20.87
Fiscal period: TTM 1Q2019
Financing Status: The company reached a definitive agreement to be acquired by iAnthus Capital Holdings (CNQ: IAN) for $835 million on October 18, 2018. The acquisition positions iAnthus as one the largest U.S. cannabis operators and expands the firm’s footprint to 10 states, nearly doubling its reach.
Number of active investors:
Profile last updated: 27-Nov-2018
Last known valuation: 835.00
Last known valuation date: 18-Oct-2018